{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:51:46Z","timestamp":1777693906997,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015503","name":"Lieber Institute for Brain Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015503","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bmcl.2024.130059","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T22:41:43Z","timestamp":1733438503000},"page":"130059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Development and characterization of pyridyl carboxamides as potent and highly selective Nav1.8 inhibitors"],"prefix":"10.1016","volume":"117","author":[{"given":"Michael","family":"Poslusney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron C.","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark L.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f3nia","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5115-9300","authenticated-orcid":false,"given":"James C.","family":"Barrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.130059_b0005","series-title":"Pain Medicine: an Essential Review","year":"2017"},{"key":"10.1016\/j.bmcl.2024.130059_b0010","first-page":"544","article-title":"Breaking barriers to novel analgesic drug development","volume":"16","author":"Yekkirala","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2024.130059_b0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1146\/annurev-pharmtox-010617-052534","article-title":"The opioid epidemic: crisis and solutions","volume":"58","author":"Skolnick","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bmcl.2024.130059_b0020","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1113\/jphysiol.2011.224204","article-title":"Voltage-gated sodium channels at 60: structure, function and pathophysiology","volume":"590","author":"Catterall","year":"2012","journal-title":"J Physiol-London"},{"key":"10.1016\/j.bmcl.2024.130059_b0025","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.1021\/jm501981g","article-title":"Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications","volume":"58","author":"Ruiz","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130059_b0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/gb-2003-4-3-207","article-title":"Overview of the voltage-gated sodium channel family","volume":"4","author":"Yu","year":"2003","journal-title":"Genome Biol"},{"key":"10.1016\/j.bmcl.2024.130059_b0035","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/brain\/aws225","article-title":"Neurological perspectives on voltage-gated sodium channels","volume":"135","author":"Eijkelkamp","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.bmcl.2024.130059_b0040","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1016\/j.bmcl.2014.06.038","article-title":"Recent progress in sodium channel modulators for pain","volume":"24","author":"Bagal","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.130059_b0045","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/09298673113206660257","article-title":"Isoform selective voltage-gated sodium channel modulators and the therapy of pain","volume":"21","author":"Jukic","year":"2014","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2024.130059_b0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuropharm.2017.04.014","article-title":"The pharmacology of voltage-gated sodium channel activators","volume":"127","author":"Deuis","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2024.130059_b0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pharmthera.2016.11.015","article-title":"Na(V)1.7 as a pain target - From gene to pharmacology","volume":"172","author":"Vetter","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2024.130059_b0060","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1474-4422(14)70024-9","article-title":"Painful and painless channelopathies","volume":"13","author":"Bennett","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bmcl.2024.130059_b0065","doi-asserted-by":"crossref","first-page":"E2724","DOI":"10.1073\/pnas.1220844110","article-title":"Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels","volume":"110","author":"McCormack","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2024.130059_b0070","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/j.pain.0000000000001227","article-title":"Efficacy of the Nav1. 7 blocker Pf-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy","volume":"159","author":"Donnell","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.bmcl.2024.130059_b0075","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(17)30005-4","article-title":"Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial","volume":"16","author":"Zakrzewska","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bmcl.2024.130059_b0080","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1212\/WNL.0000000000002333","article-title":"Sodium channel Na(v)1.8 emerging links to human disease","volume":"86","author":"Han","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.bmcl.2024.130059_b0085","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/379257a0","article-title":"A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons","volume":"379","author":"Akopian","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2024.130059_b0090","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.pain.2012.04.022","article-title":"Nav1.8 expression is not restricted to nociceptors in mouse peripheral nervous system","volume":"153","author":"Shields","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.bmcl.2024.130059_b0095","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/9195","article-title":"The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways","volume":"2","author":"Akopian","year":"1999","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bmcl.2024.130059_b0100","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.neuroscience.2007.01.054","article-title":"Small interfering RNA-mediated selective knockdown of NaV1. 8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats","volume":"146","author":"Dong","year":"2007","journal-title":"Neuroscience"},{"issue":"47","key":"10.1016\/j.bmcl.2024.130059_b0105","doi-asserted-by":"crossref","first-page":"19444","DOI":"10.1073\/pnas.1216080109","article-title":"Gain-of-function Nav1.8 mutations in painful neuropathy","volume":"109","author":"Faber","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmcl.2024.130059_b0110","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0300-9084(00)01174-3","article-title":"Molecular mechanisms of neurotoxin action on voltage-gated sodium channels","volume":"82","author":"Cestele","year":"2000","journal-title":"Biochimie"},{"key":"10.1016\/j.bmcl.2024.130059_b0115","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acsmedchemlett.5b00059","article-title":"Discovery and optimization of selective Na(v)1.8 modulator series that demonstrate efficacy in preclinical models of pain","volume":"6","author":"Bagal","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.130059_b0120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bmc.2018.12.002","article-title":"The discovery and optimization of benzimidazoles as selective NaV1. 8 blockers for the treatment of pain","volume":"27","author":"Brown","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2024.130059_b0125","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/jm070637u","article-title":"Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Na(v)1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain","volume":"51","author":"Kort","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130059_b0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2010.05.009","article-title":"A-887826 is a structurally novel, potent and voltage-dependent Na(v)1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats","volume":"59","author":"Zhang","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2024.130059_b0135","unstructured":"Hadida-Ruah S, Anderson C, Arumugam V, et al. Pyridone. Amides as Modulators of Sodium Channels. US 9051270, 2015."},{"key":"10.1016\/j.bmcl.2024.130059_b0140","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1073\/pnas.0611364104","article-title":"A-803467, a potent and selective Na(v)1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat","volume":"104","author":"Jarvis","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2024.130059_b0145","first-page":"2654","article-title":"A novel selective and orally bioavailable Na(v)1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability. Brit","volume":"172","author":"Payne","year":"2015","journal-title":"J Pharmacol"},{"key":"10.1016\/j.bmcl.2024.130059_b0150","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/pm\/pnab032","article-title":"A phase 1, randomized, double-blind, placebo-controlled, crossover study to evaluate the pharmacodynamic effects of VX-150, a highly selective NaV1. 8 inhibitor, in healthy male adults","volume":"22","author":"Hijma","year":"2021","journal-title":"Pain Med"},{"key":"10.1016\/j.bmcl.2024.130059_b0155","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV1. 8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bmcl.2024.130059_b0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3940(98)00738-1","article-title":"A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat","volume":"256","author":"Khasar","year":"1998","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bmcl.2024.130059_b0165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41380-022-01811-4","article-title":"Evaluation of Nav1. 8 as a therapeutic target for Pitt Hopkins syndrome","volume":"28","author":"Martinowich","year":"2023","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.bmcl.2024.130059_b0170","unstructured":"Hadida-Ruah S, Anderson C, Arumugam V, et al. Quinoline and Quinazoline Amides as Modulators of Sodium Channels. WO 2014120815A1, 2014."},{"key":"10.1016\/j.bmcl.2024.130059_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-019-2671-y","article-title":"Repurposing approved drugs as inhibitors of K v 7.1 and Na v 1.8 to treat Pitt Hopkins syndrome","volume":"36","author":"Ekins","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.bmcl.2024.130059_b0180","doi-asserted-by":"crossref","first-page":"14243","DOI":"10.1021\/acs.jmedchem.0c00960","article-title":"Sulfoximines as rising stars in modern drug discovery? Current status and perspective on an emerging functional group in medicinal chemistry","volume":"63","author":"M\u00e4der","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130059_b0185","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.4c00103","article-title":"2-Aminopyridines as potent and selective Nav1. 8 inhibitors exhibiting efficacy in a nonhuman primate pain model","author":"Breslin","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.130059_b0190","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/molpharm.123.000789","article-title":"Pharmacologic characterization of LTGO-33, a selective small molecule inhibitor of the voltage-gated sodium channel NaV1. 8 with a unique mechanism of action","volume":"105","author":"Gilchrist","year":"2024","journal-title":"Mol Pharmacol"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2400461X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2400461X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:24:01Z","timestamp":1737321841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2400461X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":38,"alternative-id":["S0960894X2400461X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.130059","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of pyridyl carboxamides as potent and highly selective Nav1.8 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.130059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130059"}}